Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

827
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
827

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RAS pathway targeted therapy in patients with DICER1-associated sarcomas.

NPJ precision oncology·2025
Same author

First Cases of NUT Carcinoma Harboring NUTM2 Gene Rearrangements.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2025
Same author

Pediatric Patient Experiences Using Medical Cannabis in Cancer Symptom Management as Reported by Parents of Children and Adolescents and by Young Adults.

Journal of pediatric hematology/oncology nursing·2025
Same author

Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.

Genome medicine·2024
Same author

"Oncocytoid Renal Cell Carcinomas After Neuroblastoma" Represent TSC -mutated Eosinophilic Solid and Cystic Renal Cell Carcinomas : Association With Prior Childhood Malignancy and Multifocality With Therapeutic Implications.

The American journal of surgical pathology·2023
Same author

Children's Oncology Group 2023 blueprint: Nursing discipline.

Pediatric blood & cancer·2023

Related Experiment Video

Updated: May 5, 2026

Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
11:09

Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging

Published on: July 14, 2010

41.4K

Naxitamab for Relapsed/Refractory Neuroblastoma.

Teresa Herriage1, Jawhar Rawwas1, Adam Sterman2

  • 1Cancer and Blood Disorders Program, Children's Minnesota, Minneapolis, MN, USA.

Journal of Pediatric Hematology/Oncology Nursing
|February 19, 2026
PubMed
Summary

Naxitamab immunotherapy can be safely administered in outpatient settings for relapsed/refractory neuroblastoma. An interdisciplinary team approach effectively manages adverse events, allowing patients to receive treatment and return home the same day.

Keywords:
medication administrationneuroblastomanursing careoncology diagnosissolid tumortargeted therapy

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
03:53

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

696

Related Experiment Videos

Last Updated: May 5, 2026

Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
11:09

Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging

Published on: July 14, 2010

41.4K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
03:53

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

696

Area of Science:

  • Pediatric Oncology
  • Immunotherapy
  • Clinical Pharmacy

Background:

  • Relapsed/refractory (R/R) neuroblastoma presents significant treatment challenges due to disease resistance.
  • Naxitamab, a GD2-targeting monoclonal antibody, is approved for R/R high-risk neuroblastoma.
  • Severe nerve pain is a notable adverse event associated with naxitamab treatment.

Purpose of the Study:

  • To present naxitamab, an immunotherapy for R/R neuroblastoma.
  • To discuss the adverse events (AEs) associated with naxitamab.
  • To describe an institutional approach for administering naxitamab in an outpatient infusion center.

Main Methods:

  • Development of a standardized, adaptable care plan by an interdisciplinary team led by a pediatric oncology advanced practice nurse.
  • Inclusion of diverse roles: nursing, physician specialists, pharmacists, psychosocial staff, patients, and families.
  • Comprehensive education for each team member regarding their defined responsibilities.

Main Results:

  • Effective management of adverse events during naxitamab infusions.
  • Safe administration of naxitamab in an outpatient infusion center over multiple treatment cycles.
  • Patients discharged home within 2 hours post-infusion completion.

Conclusions:

  • Outpatient naxitamab administration necessitates meticulous planning and execution by a prepared interdisciplinary team.
  • This ambulatory care model enhances patient and family quality of life.
  • Successful management of AEs supports the feasibility of outpatient immunotherapy delivery.